Extended Data Fig. 9: Antibody-mediated protection against SARS-CoV-2 variants in 129S2 mice.
From: In vivo monoclonal antibody efficacy against SARS-CoV-2 variant strains
a–h, Six-to-seven-week-old female and male immunocompetent 129S2 mice received 40 μg (about 2 mg kg−1) of the indicated mAb treatment by intraperitoneal injection one day before intranasal inoculation with 103 FFU of WA1/2020 N501Y/D614G, Wash-B.1.351 or Wash-B.1.1.28 or 105 FFU of B.1.1.7. Tissues were collected at three days after infection. Viral RNA levels in the lung (a–d) or nasal washes (e–h) were determined (line indicates median; in order from left to right n = 12, 8, 6 and 5 (a); n = 12, 7, 9 and 10 (b); n = 11, 9, 8 and 10 (c); n = 14, 9, 6 and 5 (d); n = 14, 5, 9 and 9 (e); n = 11, 7, 9 and 10 (f); n = 10, 9, 8 and 10 (g); n = 15, 9, 7 and 10 (h) mice per group, pooled from two to three experiments; one-way ANOVA with Dunnett’s test with comparison to control mAb: ns, not significant, ***P < 0.001; ***P = 0.0009, *P = 0.0176, **P = 0.0077 (c); **P = 0.0042, ***P = 0.0001 (left), 0.0010 (right) (d); *P = 0.0467 (left), 0.0188 (right) (e); **P = 0.0059, ***P = 0.0002 (left), 0.0004 (right) (f); *P = 0.0184 (g), *P = 0.0129, **P = 0.0090 (h)). Dotted line indicates the limit of detection of the assay.
